|
Oct 2
|
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability
|
|
Sep 25
|
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
|
|
Jul 25
|
While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate
|
|
Jun 13
|
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
|
|
Jun 13
|
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
|
|
Jun 12
|
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
|
|
May 21
|
What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?
|
|
May 17
|
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
|
|
May 15
|
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
|
|
May 9
|
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Released Its First-Quarter Earnings: Here's What Analysts Think
|
|
May 8
|
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Heron Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 8
|
Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ...
|
|
May 7
|
Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates
|
|
May 7
|
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
|
|
May 7
|
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 7
|
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
|
|
May 2
|
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
|
|
Apr 30
|
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
|
|
Apr 25
|
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Profit Outlook
|